

COVID-19 Vaccine Tested on Babies and Pregnant Women

By [National Vaccine Information Centre \(NVIC\)](#)

Global Research, March 16, 2021

[Mercola](#)

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles **can be read in 27 languages by activating the “Translate Website”** drop down menu on the top banner of our home page (Desktop version).

Pharmaceutical and medical device giant Johnson & Johnson, Inc. (J&J) announced on February 28, 2021, plans to test its experimental Ad26.COVS vaccine for COVID-19 on infant children (including newborns), pregnant women and people with compromised immune systems.

J&J did not include infants, pregnant women or the immunocompromised in the U.S. population in clinical trials on the experimental COVID-19 vaccine last year.^{1,2,3} A recent article in New York Magazine noted:⁴

“The initial clinical trials for COVID-19 vaccines didn’t include children, which is standard practice; now, trials for younger children are happening in descending order of age, calibrating the best dosage for each cohort.”

The announcement by J&J came the day after the U.S. Food and Drug Administration (FDA) granted J&J subsidiary Janssen Biotech Inc. an emergency use authorization (EUA) to distribute the vaccine in the U.S. for use by individuals 18 years of age and older. Currently, the single-dose Ad26.COVS vaccine cannot be given to anyone in the U.S. under 18 years old.^{5,6,7,8,9}

According to a spokesperson for Janssen, which manufactures Ad26.COVS, the single-dose vaccine will first be tested on children between 12 and 18 years old. Afterward, J&J will proceed quickly to test the vaccine on infants, pregnant women and immunocompromised people.¹⁰

FDA Reviewed J&J Plans to Test COVID-19 Vaccine on Babies

J&J’s move to test its COVID-19 vaccine on very young children, as well as pregnant woman and immunocompromised people, was expected. The plans to perform these clinical trials were reportedly included in J&J’s application to the FDA for EUA and were discussed by members of the FDA advisory committee that reviewed J&J’s data on Ad26.COVS.^{11,12}

“They (J&J) did not get into a lot of detail about it but did make it clear they will be pursuing pediatric and maternal coronavirus immunization studies,” said FDA advisory committee member Dr. Ofer Levy, Ph.D., director of the Precision Vaccines Program at Harvard University’s Boston Children’s Hospital.¹³

Other Companies Testing COVID-19 Vaccines on Older Children

J&J’s planned COVID-19 vaccine clinical trials will be the first to include infants. AstraZeneca plc, which has produced the experimental AZD1222 vaccine for COVID-19 in partnership with Oxford University, has been conducting clinical trials on children as young as 6 years of age, while Moderna Inc. and Pfizer Inc. (in partnership with BioNTech SE) are currently testing their experimental mRNA-1273 and BNT162b2 COVID-19 vaccines on children as young as 12.^{14,15}

J&J began shipping out 4 million doses of Ad26.COV2.S on March 1, 2021. The company has pledged that it will have 20 million doses of the vaccine ready to distribute by the end of March and 100 million doses by this summer.¹⁶

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Notes

¹ [Farmer B. Johnson & Johnson to test new one-shot Covid-19 vaccine on babies. The Daily Telegraph Mar. 1, 2021](#)

^{2, 10, 11, 13} [Kolata G. Johnson & Johnson has planned trials of its vaccine that will include infants. The New York Times Feb. 28, 2021](#)

^{3, 4, 16} [Rosa-Aquino P. Johnson & Johnson Will Run COVID Vaccine Trials on Infants. New York Magazine Mar. 1, 2021](#)

⁵ [Lovelace B. FDA approves Johnson & Johnson’s single-shot Covid vaccine for emergency use. CNBC Feb. 28, 2021](#)

⁶ [Press release. Johnson & Johnson Feb. 27, 2021](#)

⁷ [U.S. Food and Drug Administration. Janssen COVID-19 Vaccine. Mar. 1, 2021](#)

⁸ [FDA authorizes Johnson & Johnson’s one-dose COVID-19 vaccine, doses expected to start rolling next week. USA Today Mar. 2, 2021](#)

⁹ [Coleman K. If You’re This Age, You Can’t Get the Johnson & Johnson Vaccine Yet. Yahoo! Finance Mar. 2, 2021](#)

¹² [Branswell H, Herper M. FDA advisory panel endorses Johnson & Johnson COVID-19 vaccine. STAT Feb.](#)

[26, 2021](#)

¹⁴ [Hein A. Oxford-AstraZeneca testing COVID-19 vaccine in children as young as 6. Fox News Feb. 15, 2021](#)

¹⁵ [Mandavilli A. Covid Vaccines for Kids Are Coming, but Not for Many Months. The New York Times Feb. 12, 2021](#)

Featured image is from Mercola

The original source of this article is [Mercola](#)

Copyright © [National Vaccine Information Centre \(NVIC\)](#), [Mercola](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [National Vaccine Information Centre \(NVIC\)](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca